Available Until 9/16/2024

Pediatric Self-Assessment Program (PEDSAP) Book 1: Pulmonary and Endocrinology (Cert # L249119)

ACPE Numbers: Various – see listing below
Release Date: March 15, 2024
Expiration Dates: September 16, 2024
Activity Type: Application-based
CE Credits: 18.5 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non-member) 

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to 18.5 contact hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ACCP and ASHP professional development program for BCPPS recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

The target Pediatric Self-Assessment Program (PEDSAP) Book 1: Pulmonary and Endocrinology is board-certified and advanced level pediatric care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 18.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCPPS.

Learning Activity

Passing Score

Credit Information

Pulmonary and Endocrinology I


5.0 Contact Hours

ACPE: 0217-9999-24-031-H01-P

Pulmonary and Endocrinology II


4.0 Contact Hours

ACPE: 0217-9999-24-032-H01-P

Pulmonary and Endocrinology III


4.5 Contact Hours


ACPE: 0217-9999-24-033-H01-P

Pulmonary and Endocrinology IV


5.0 Contact Hours

ACPE: 0217-9999-24-034-H01-P

Pulmonary and Endocrinology I
ACPE #: 0217-9999-24-031-H01-P
Chapter: Asthma Guideline Updates

  • Analyze similarities and differences in clinical guideline recommendations for asthma pharmacologic management.
  • Design an appropriate therapeutic plan for treatment of a pediatric patient with severe asthma.
  • Evaluate benefits and limitations of currently available inhalation drug delivery devices. 

Chapter: Treatment Advances for Inherited Disorders

  • Demonstrate difficulties in development of medications for patients with an inherited disorder.
  • Evaluate clinical signs and symptoms associated with inborn errors of metabolism (IEM).
  • Construct a pharmacotherapeutic regimen for a patient with a newly diagnosed IEM.
  • Design a treatment regimen for a child with an inherited neuromuscular disorder.
  • Assess barriers to treatment of rare diseases encountered by patients and their care teams. 

Pulmonary and Endocrinology II
ACPE #: 0217-9999-24-032-H01-P
Chapter: Endocrine Updates: Diabetes and Contraception

  • Assess the role of novel therapies, such as biosimilar insulins and anti-CD3 antibodies, in the management of diabetes in a pediatric population.
  • Design a therapeutic plan for a pediatric patient with type 2 diabetes.
  • Evaluate the advantages, limitations, and clinical evidence for the use of new diabetes technologies, including continuous glucose monitors and insulin pumps.
  • Develop a strategy for counseling an adolescent patient wishing to start contraception.
  • Distinguish between appropriate contraceptive options for adolescent patients. 

Chapter: Obesity Management

  • Analyze factors and considerations that contribute to pediatric patients with overweight and obesity.
  • Design patient-specific nonpharmacologic interventions into a comprehensive care regimen for a pediatric patient with overweight and obesity.
  • Evaluate pharmacotherapeutic options for a pediatric patient with overweight or obesity. 

Pulmonary and Endocrinology III
ACPE #: 0217-9999-24-033-H01-P
Chapter: Pediatric Pharmaceutical Counseling Strategies

  • Assess similarities and differences between patient-centered and equitable-based pharmaceutical counseling strategies.
  • Analyze key elements of an effective and standardized medication counseling process.
  • Convert existing written medication instructions to be pediatric friendly and incorporate best practices that support caregiver understanding of information.
  • Evaluate benefits and barriers of using technology and online platforms to improve access to high-quality pediatric medication information for children, young people, and their adult caregivers.
  • Apply child-centered and equitable-based practices into medication education strategies that cultivate pediatric autonomy and self-management across health care and non-health care settings. 

Chapter: Pediatric Compounding and Operations Management

  • Assess systems to ensure appropriate drug delivery throughout the medication use process.
  • Evaluate equipment, technology, and clinical decision support involved in the medication use process.
  • Develop a preferred formulary that supports appropriate pediatric dosing.
  • Justify policy and procedures for the management of pediatric patients through evidence-based practice guidelines and protocols.
  • Analyze the clinical and financial impact and value of pediatric pharmacy services. 

Pulmonary and Endocrinology IV
ACPE #: 0217-9999-24-034-H01-P
Case Series: Biologics in Asthma Care

  • Distinguish between the different asthma phenotypes using patient-specific factors and laboratory biomarkers.
  • Produce an evidence-based plan for the management of allergic and eosinophilic asthma phenotypes.
  • Design an evidence-based plan for the management of phenotypic asthma in the setting of comorbidities.
  • Develop strategies for overcoming barriers to care with a focus on patient-specific, provider-specific, and payer-specific criteria. 

Case Series: Metabolic Bone Disease

  • Evaluate medications used to improve outcomes in children with hereditary metabolic bone diseases (MBDs).
  • Distinguish dietary intake and supplement requirements for the management of bone disease resulting from vitamin and mineral insufficiency.
  • Develop strategies for the management of MBD occurring secondary to other chronic pediatric disease states.
  • Distinguish medications known to increase the risk of reduced bone mineral density warranting increased monitoring in children. 

Case Series: Neonatal Hypoglycemia

  • Evaluate the severity of neonatal hypoglycemia incorporating patient-specific history and laboratory values.
  • Develop an evidence-based treatment plan for the management course of hypoglycemia in a neonatal patient.
  • Assess factors that must be considered when developing and implementing a treatment plan for a neonatal patient with moderate to severe hypoglycemia.

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

Consultancies: Letitia M. DeLaine (EngageGrowThrive/Abbott); Cameron J. McKinzie (Vertex Pharmaceuticals)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on pediatric pharmacy activities.